Carmen D. Zorrilla to Vaccines, Synthetic
This is a "connection" page, showing publications Carmen D. Zorrilla has written about Vaccines, Synthetic.
Connection Strength
0.106
-
Fong Y, Huang Y, Huang Y, Woo W, McGarry A, ??ez G, Dunkle LM, Cho I, Houchens CR, Martins K, Jayashankar L, Castellino F, Petropoulos CJ, Leith A, Haugaard D, Webb W, Lu Y, Yu C, Carpp LN, Randhawa AK, Andrasik MP, Kublin JG, Hutter J, Keshtkar-Jahromi M, Beresnev TH, Rodriguez CA, Tapia M, Turley CB, Zorrilla CD, Cohen SH, Kline SE, Barranco E, Corey L, Neuzil KM, Follmann D, Ake JA, Gay CL, Kotloff KL, Jones T, Koup RA, Donis RO, Gilbert PB. Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine. Clin Infect Dis. 2026 Apr 30; 82(4):e863-e874.
Score: 0.060
-
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012 Jul 15; 206(2):258-66.
Score: 0.046